ANDA 211661, held by Hainan Poly Pharm. Voriconazole.
As of Nov 21, 2026, ANDA 211661 (Voriconazole), held by Hainan Poly Pharm, was first approved by FDA on Nov 30, 2018, with 6 approved supplements and 0 published complete response letters.
Voriconazole for injection is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: Invasive aspergillosis Candidemia in non-neutropenics and other deep tissue Candida infections Esophageal candidiasis Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani, in patients intolerant of, or refractory to, other therapy 1.1 Invasive Aspergillosis Voriconazole for injection is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 30, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Voriconazole200MG/VIAL · powder;intravenous | Voriconazole | Rx |
| Nov 16, 2026 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jun 23, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Aug 10, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 10, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 10, 2021 | Supplement 8Labeling · Standard review | Approved | None posted |
| Aug 10, 2021 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 30, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters